Cytokine signature in convalescent SARS-CoV-2 patients with inflammatory bowel disease receiving vedolizumab.

Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
02 Jan 2024
Historique:
received: 26 09 2023
accepted: 14 12 2023
medline: 4 1 2024
pubmed: 4 1 2024
entrez: 3 1 2024
Statut: epublish

Résumé

While differential antibody responses SARS-CoV-2 in patients with inflammatory bowel disease (IBD) receiving infliximab and vedolizumab are well-characterized, the immune pathways underlying these differences remain unknown. Prior to COVID-19 vaccine development, we screened 235 patients with IBD receiving biological therapy for antibodies to SARS-CoV-2 and measured serum cytokines. In seropositive patients, we prospectively collected clinical data. We found a cytokine signature in patients receiving vedolizumab who are seropositive compared with seronegative for SARS-CoV-2 antibodies that may be linked to repeated SARS-CoV-2 infections. However, there were no differences between seropositive and seronegative patients receiving infliximab. In this single-center cohort of patients with IBD with anti-SARS-CoV-2 antibodies at the onset of the COVID-19 pandemic, and therefore without influence of vaccination, there is a cytokine signature in patients receiving vedolizumab but not infliximab. These findings lay the groundwork for further studies on immune consequences of viral infection in patients with IBD, which is postulated to evolve from aberrant host-microbe responses.

Identifiants

DOI: 10.1038/s41598-023-50035-1 PMID: 38168138
pubmed: 38168138
doi: 10.1038/s41598-023-50035-1
pii: 10.1038/s41598-023-50035-1
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

186

Subventions

Organisme : Leona M. and Harry B. Helmsley Charitable Trust
ID : 2107-04731

Investigateurs

Jessica Anne Neil (JA)
Stela Sota (S)
Kyung Ku Jang (KK)
Krystal Ching (K)
Mericien Venzon (M)
Xiaomin Yao (X)
Lucie Bernard (L)
Xin Chen (X)
Michael Tankelevich (M)
Reema Navalurkar (R)
Rebekah Dixon (R)
Drew S Helmus (DS)
Marcia Mukanga Lange (MM)
Emily Spiera (E)
Lodoe Sangmo (L)

Informations de copyright

© 2024. The Author(s).

Références

Kennedy NA, Goodhand JR, Bewshea C, et al. Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab. Gut2021. p. gutjnl-2021–324388.
Kennedy, N. A. et al. Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. Gut 70(10), 1884–1893. https://doi.org/10.1136/gutjnl-2021-324789 (2021).
doi: 10.1136/gutjnl-2021-324789 pubmed: 33903149
Edelman-Klapper, H. et al. Lower serologic response to COVID-19 mRNA vaccine in patients with inflammatory bowel diseases treated with anti-TNFα. Gastroenterology 162(2), 454–467. https://doi.org/10.1053/j.gastro.2021.10.029 (2022).
doi: 10.1053/j.gastro.2021.10.029 pubmed: 34717923
Lin, S. et al. Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab. Nat. Commun. 13(1), 1379. https://doi.org/10.1038/s41467-022-28517-z (2022).
doi: 10.1038/s41467-022-28517-z pubmed: 35296643 pmcid: 8927425
Wellens, J. et al. Combination therapy of infliximab and thiopurines, but not monotherapy with infliximab or vedolizumab, is associated with attenuated IgA and neutralisation responses to SARS-CoV-2 in inflammatory bowel disease. Gut https://doi.org/10.1136/gutjnl-2021-326312 (2021).
doi: 10.1136/gutjnl-2021-326312 pubmed: 34911744
Wong, S. Y. et al. Geography influences susceptibility to SARS-CoV-2 serological response in patients with inflammatory bowel disease: Multinational analysis from the ICARUS-IBD consortium. Inflamm. Bowel Dis. https://doi.org/10.1093/ibd/izad097 (2023).
doi: 10.1093/ibd/izad097 pubmed: 37951594
Lucas, C. et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature 584(7821), 463–469. https://doi.org/10.1038/s41586-020-2588-y (2020).
doi: 10.1038/s41586-020-2588-y pubmed: 32717743 pmcid: 7477538
Sekine, T. et al. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell 183(1), 158-168.e14. https://doi.org/10.1016/j.cell.2020.08.017 (2020).
doi: 10.1016/j.cell.2020.08.017 pubmed: 32979941 pmcid: 7427556
Stanczak, M. A. et al. IL-33 expression in response to SARS-CoV-2 correlates with seropositivity in COVID-19 convalescent individuals. Nat. Commun. 12(1), 2133. https://doi.org/10.1038/s41467-021-22449-w (2021).
doi: 10.1038/s41467-021-22449-w pubmed: 33837219 pmcid: 8035172
Buszko, M. et al. Lessons learned: New insights on the role of cytokines in COVID-19. Nat. Immunol. 22(4), 404–411. https://doi.org/10.1038/s41590-021-00901-9 (2021).
doi: 10.1038/s41590-021-00901-9 pubmed: 33723418 pmcid: 9317654
Gaebler, C. et al. Evolution of antibody immunity to SARS-CoV-2. Nature 591(7851), 639–644. https://doi.org/10.1038/s41586-021-03207-w (2021).
doi: 10.1038/s41586-021-03207-w pubmed: 33461210 pmcid: 8221082
Munitz, A. et al. Rapid seroconversion and persistent functional IgG antibodies in severe COVID-19 patients correlates with an IL-12p70 and IL-33 signature. Sci. Rep. 11(1), 3461. https://doi.org/10.1038/s41598-021-83019-0 (2021).
doi: 10.1038/s41598-021-83019-0 pubmed: 33568715 pmcid: 7876035
Hufnagel, K. et al. Discovery and systematic assessment of early biomarkers that predict progression to severe COVID-19 disease. Commun. Med. 3(1), 51. https://doi.org/10.1038/s43856-023-00283-z (2023).
doi: 10.1038/s43856-023-00283-z pubmed: 37041310 pmcid: 10089829
Klann, K. et al. Growth factor receptor signaling inhibition prevents SARS-CoV-2 replication. Mol. Cell 80(1), 164-174.e4. https://doi.org/10.1016/j.molcel.2020.08.006 (2020).
doi: 10.1016/j.molcel.2020.08.006 pubmed: 32877642 pmcid: 7418786
Izadi, Z. et al. Association between tumor necrosis factor inhibitors and the risk of hospitalization or death among patients with immune-mediated inflammatory disease and COVID-19. JAMA Netw. Open 4(10), e2129639–e2129639. https://doi.org/10.1001/jamanetworkopen.2021.29639 (2021).
doi: 10.1001/jamanetworkopen.2021.29639 pubmed: 34661663 pmcid: 8524310

Auteurs

Simone Dallari (S)

Department of Microbiology, New York University Grossman School of Medicine, New York, USA.

Vicky Martinez Pazos (V)

The Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1069, New York, NY, 10029, USA.

Juan Munoz Eusse (J)

Icahn School of Medicine at Mount Sinai, New York, USA.

Judith Wellens (J)

Department of Gastroenterology and Hepatology, Leuven University Hospitals, Leuven, Belgium.

Craig Thompson (C)

Division of Biomedical Sciences, Warwick Medical School, University of Warwick, Warwick, UK.

Jean-Frederic Colombel (JF)

The Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1069, New York, NY, 10029, USA.

Jack Satsangi (J)

Nuffield Department of Medicine, Translational Gastroenterology Unit, University of Oxford, Oxford, UK.

Ken Cadwell (K)

Division of Gastroenterology and Hepatology, Department of Medicine, Department of Systems Pharmacology and Translational Therapeutics, Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.

Serre-Yu Wong (SY)

The Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1069, New York, NY, 10029, USA. Serre-Yu.Wong@mountsinai.org.

Classifications MeSH